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Inflammatory bowel disease (IBD) including ulcerative colitis 
and crohn’s disease is caused by chronic inflammation in the 
digestive tract. Even though the exact pathogenesis remains 
unclear, dysbiosis of gut microbiota, damage of epithelial 
integrity, imbalance of cytokine profile and infection of specific 
pathogenic bacteria have been considered as the primary factors 
for triggering IBD. For developing probiotics which could 
positively modulate gut microbiota and immune response, this 
study aimed to screen and characterize putative probiotics with 
various functions to alleviate intestinal inflammation associated 
with IBD. First, using selective and differential media, 399 lactic 
acid bacteria (LAB) were isolated from 77 traditional fermented 
food samples produced in Gangwon province, Korea. Second, 10 
strains with putative functional LAB were screened and selected 
based on the probiotic properties, such as resistance to 
intestinal conditions, safety assessment and adhesion ability for 
human epithelial cell line. Then, the selected bacterial strains 
were evaluated for their antimicrobial activities against 
pathogens, particularly related to IBD by disk diffusion and 
agar-well diffusion methods and ATP assay. Almost every 
strains showed inhibition activities against pathogen indicators 
except the strain of B4 compared to reference strain, LGG. 





excessive intestinal inflammation were assessed by nitric oxide 
(NO) assay using murine macrophage RAW264.7 cell line. In 
addition, concentration of IL-8 produced by HT-29 cells and 
the expression levels of tight junction proteins in caco-2 cells 
which were both treated by 10 ng/ml of TNF-α were 
significantly regulated positively. After inducing colitis in mice 
by administration of 2.5 and 5 % DSS for 3 days, LGG, HS-2 
and NG-4 strains were treated orally for 14 days to verify the 
attenuation effects of intestinal inflammation. The groups of 
NG-4 treatment showed increased average feed intake, better 
survival, less DAI scores, shortening of the colon length, 
modulating gut microbiota positively and upregulating the 
expression of TJ proteins compared to LGG group. In conclusion, 
Pediococcus acidilactici NG-4 is anticipated to have 
possibilities and apply as probiotics for IBD patients to alleviate 
the symptoms of intestinal inflammation followed by clinical 
tests. 
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Chapter 1. Introduction 
 
Bowel disorders, encompassing irritable bowel syndrome (IBS) 
and inflammatory bowel disease (IBD), are considered as a general 
concern as the incidence and prevalence rates of these disorders have 
increased annually all over the world for decades. IBD, which is mainly 
comprised of ulcerative colitis (UC) and crohn’s disease (CD), is a 
group of intestinal disorders that chronically cause inflammation 
through the intestinal tract. Although the exact pathogenesis of IBD is 
still unclear, the main factors of IBD have been considered as the 
dysbiosis of intestinal microbiota which means the disruption of 
normal composition in gut microbiota, damage of epithelial cell 
integrity and infection of specific pathogens including Campylobacter 
coli, Campylobacter jejuni, Escherichia coli and Helicobacter pylori 
(Hold et al., 2014). The gut microbiota, a complex community of 
microorganisms residing in the gastrointestinal tracts of mammals 
including human, have been suggested as a key effector in 
pathogenesis and prevention of IBD (Guinane and Cotter, 2013). 
 Probiotics are recognized as live microorganisms that are 
believed to provide health benefits when consumed in sufficient 
quantities (Butel, 2014). According to recent studies, probiotics  
confer various health promoting effects, such as modification of the 
gut microbiota, improvement of epithelial barrier integrity, and anti-





inflammatory response induced by pathogens (Sánchez et al., 2017).  
In this study aimed to screen potential probiotic bacteria isolated 
from Korean traditional fermented foods and investigate 
functionalities of selected lactic acid bacteria, such as gut microbiota 
modulation, antimicrobial activity, anti-inflammatory effects and 
regulation of tight junction proteins expression, leading to attenuation 















Chapter 2. Review of Literature 
 
2.1. Gut immunity 
2.1.1. Mucosal immune system 
The mucosal immune system of vertebrates directly contacts with 
the external environment and constitutes mucosal barrier surfaces. It 
includes the mucosa-associated lymphoid tissues (MALT) related to 
mucosal surfaces and is classified with several constituents containing 
gut-associated lymphoid tissue (GALT), nasopharinx-associated 
lymphoid tissue (NALT), the salivary and mammary glands, the 
urogenital organs and bronchus-associated lymphoid tissue (BALT). 
The mucosal tissues populated with immune cells are crucial to 
prevent infection from the external surroundings and to provoke more 
antibodies production than any other parts in the body. Furthermore, 
they contain the specialized epithelial cell barrier exhibiting surface 
protection to protect the pathogens from penetrating the internal lining 
of tissues and administering tolerance against intact antigens such as 
commensal bacteria (McGhee et al., 1992). 
The lymphoid components of GALT are classified with organized 
mucosa associated lymphoid tissue which contains mucosal follicles 
acting as inducers of the primary immune response, and the diffuse 
mucosa associated lymphoid tissue which is composed of scattering 





(Baumgart and Dignass, 2002). The organized tissues include 
Peyer’s patches which aggregated lymphoid tissue compounds in the 
submucosa parts of small intestine and mesenteric lymph nodes 
(MLNs) connected to both vilus lamina propria and Peyer’s patches 
(Mowat, 2003). The diffuse mucosa-associated lymphoid tissue, the 
less organized components, encompasses the lamina propria and 
intestinal epithelium. Various immune cells, such as T cells, B cells, 
dendritic cells, neutrophils, macrophages and mast cells can be found 
in the intestinal lamina propria of adult human (Prosper and Boyaka, 
2013). The antigens penetrated through the epithelium may be 
progressed and recognized by the CD4+ T cells proliferating cytokines 
extensively. 
The intestinal epithelium, largest part of the body’s mucosal sides, 
is lined with a monolayer of cells derived from villi and crypts. 
Intestinal epithelial cells (IECs) have key roles to separate host and 
luminal microorganisms by recognizing stimulation of intestinal 
commensal bacteria and facilitating to reinforce mucosal barrier 
function. They are constantly replaced by intestinal epithelial stem 
cells located at the base of the crypts and regulate essential immune 
functions. There are several types of cells in secretory IECs, 
containing goblet cells, peneth cells, and enteroendocrine cells 
specialized to digestive or epithelial barrier functions (Peterson and 
Artis, 2014). Secretory goblet cells and peneth cells settles and 





antimicrobial proteins (AMPs) to inhibit translocation of luminal 
microbial and food antigens (Kim and Ho, 2010).  
 
2.1.2. Immune homeostasis 
IECs have the central capacity of maintaining barrier function 
against external environment and intestinal homeostasis by 
performing as a primary sensors to segregate signals of luminal 
commensal bacteria from that of microbial encounters and control 
anti-microbial and immune responses.  
IECs exhibit pattern-recognition receptors (PRRs) that are 
receptor molecules to identify pathogen-associated molecular 
patterns (PAMPs), well-known as flagellin, lipopolysaccharide, 
bacteria-derived DNA and RNA. PRRs are specialized to induce innate 
immunity system and act as a crucial sensor for protection against 
pathogens. Majority of PRRs can be classified with three groups: Toll-
like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLRs) and NOD-like receptors (NLRs). These PRRs 
induce individual pathways to recognize ligands or inherent signals of 
pathogenic bacteria related to pathogenesis (Kamada et al., 2013). 
Specifically,  
TLR families are presented on the bacterial surfaces and interior 
side of endosomes and prompt activation of myeloid differentiation 
primary response 88 protein, known as downstream adaptor 





interferon-β (TRIF) while stimulated by bacterial components. They 
have been estimated to induce proliferation of epithelium cells, IgA 
production, conservation of tight junction integrity and antimicrobial 
molecules secretion, which are crucial roles to maintain homeostasis 
in intestine when recognizing signals of TLR. There are various sorts 
of TLRs in humans, including TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, 
TLR7, TLR8, TLR9, TLR10, TLR11(Mahla et al., 2013). TLR2 and 
TLR 4 are exhibited by IECs at low levels in human colon tissues with 
normal condition (Abreu, 2010). While TLR3 has shown to be 
plentifully expressed in small intestine and colon of normal human, 
TLR5 is mainly represented in the colon(Cario and Podolsky, 2000). 
Recently, several studies using germ-free mice have 
demonstrated that the intestinal epithelium and commensal bacteria 
stimulate a complex progress that is featured by exhibition of genes 
enhancing tight junction proteins (Hooper et al., 2001). The apical pole 
of epithelial cells is connected by tight junction (TJ) complexes to 
block the transportation of bacteria and PAMPs through the passages 
between IECs (Bischoff et al., 2014). The major TJ complex includes 
transmembrane proteins characterized with occludin, junctional 
adhesion molecules (JAM) and claudins family members depending on 
the position and permeability regulation. Zonula occludens located in 
the upper part of epithelium cell interact with occludin and claudins as 
connected with the actin cytoskeleton and regulate cycle and polarity 





permeability by transferring selectively ions, solutes, small sized 
molecules between epithelium cells. Assembly and disassembly of TJ 
complexes exert an energetic process including migration, 
endocytosis, and recycling (Konig et al., 2016). TJ dynamics can be 
modulated by several cytokines (Petecchia et al., 2012). For instance, 
tumor necrosis factor-α (TNF- α) can modulate and promote 
permeability in TJ proteins through upregulating the expression of 
claudin-2 which controls selectively cation-channel through 
phosphatidylinositol-3-kinase signaling (Mankertz et al., 2009).  
 
2.1.3. Gut microbiota  
The surfaces of vertebrates including skin and mucosal layer are 
settled by large amounts of microorganisms such as bacteria, viruses, 
fungi, parasites which normally represented to the microbiota. There 
are extremely plenty of microorganism, mainly bacteria, most of which 
colonize gastrointestinal and oral tract more than 100 trillion 
microorganisms. Particularly, most of them have resided in the colon 
for millions of years by establishing a cooperative relationship. The 
host has evolved to supply microbiota habitation and nutrients as 
necessary requisite for survival of bacteria and, in turn the microbiota 
serve many physiological effects for contributing health of host 
(Hooper and Macpherson, 2010). The leading roles of the microbiota 
for promotion of health in host contain abilities to fermentation and 





gut immune responses which modulate the formation of the microbiota 
and inhibition of pathogen colonization (Renz et al., 2012). In gut 
immune system, microbiota have an essential role of developing 
lymphoid tissue including GLATs, TH 17 cells, Treg cells, IgA-
producing B cells, plasma cells and innate lymphoid cells through 
plenty of in vivo studies using germ free mice (Kamada et al., 2013). 
It has been understood the importance and relationships between 
gut microbiota and immune function by investigating that disruption of 
gut microbiota composition can influence gastrointestinal conditions 
and cause various disease associated with immune dysfunction, such 
as inflammatory bowel disease and intestinal inflammation (Frank et 
al., 2007) and systematic diseases encompassing diabetes (Qin et al., 
2012) and obesity (Zhang et al., 2009).  
Along with development of metagenomics technology to analysis 
the full genetic composition of community, the studies of gut 
microbiota have been extremely activated to determine potential 
functions as microbes constitution for decades (Ley et al., 2008). 
Using these newly developed technologies, it has been known that 
gastrointestinal microbial community of healthy individuals maintains 
gut homeostasis between beneficial bacteria and harmful bacteria 
which are potential to bring about infections induced by pathogens. 
However, the disruption of normal composition in gut microbiota, 
designated as dysbiosis, can be caused under specific states including 





conditions (Honda and Littman, 2012). Dysbiosis also associated with 
the abnormal conditions of accumulating and increasing virulence 
certain kinds of commensal bacteria and can transform these normal 
conditions into pathobionts which are constant colitogenic conditions 
triggering intestinal inflammation. Therefore, maintaining gut 
homeostasis through regulation of these microbiota composition is 
extremely crucial for exerting health benefits and preventing intestinal 


















2.2. Bowel disorders 
2.2.1. Irritable bowel syndrome (IBS) 
Irritable bowel syndrome (IBS) belongs to functional bowel 
disorders which accompany persistent conditions characterized with 
physical and mental illness, abdominal discomfort, constipation and 
diarrhea induced by uncertain bowel motility. It can be diagnosed 
solely using symptoms-based criteria, referred to as Rome 
diagnostic criteria due to absence of obvious organic lesion (Häuser 
et al., 2012). Although IBS is not recognized as severe illness, its 
incidence has increased about 10 ~15 % between adults suffered 
from this disorder (Longstreth et al., 2006).  
There have been numerous attempts to investigate the 
pathophysiology of IBS, but the exact cause of it is still unclear. While 
changed brain-gut relations has been considered as a main 
mechanisms of pathogenesis in IBS for decades, recently studies 
have suggested changes of gut microbiota composition and 
inflammation associated immune activation at the low level as novel 
mechanisms of IBS (Brint et al., 2011). Dysbiosis of gut microbiota 
also is speculated to facilitate adhesion ability of pathogens to wall of 
bowel surfaces in pathogenesis of IBS (Ghoshal et al., 2012). 
Particularly, the gut microbiota profile of IBS patients has specific 
features of high proportion of Fimicutes genus, such as Ruminococcus, 





Bifidobacterium and Faecalibacterium species (Rajilić–Stojanović et 
al., 2011).  
 
2.2.2. Inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD) has been intermittently 
observed since long before (Mulder et al., 2014) and considered as 
increasing and significant bowel disorders in developed countries 
(Molodecky et al., 2012). The worldwide incidence of IBD has been 
investigated by an organized review of over 200 countries-based 
researches. In Western world, IBD is characterized by highest 
prevalence, influencing over 0.5 % of the ordinary population, 
whereas it occurs at low level in Mediterranean and Eastern Asia. 
Although IBD has been conventionally considered as a disorder of 
Caucasian residing in developed countries of the Western part, as 
developing countries in Eastern and Mediterranean world has become 
westernized, prevalence and incidence rates of IBD has increased the 
same trends of Western world (Kaplan, 2015). 
IBD encompassing two main groups of ulcerative colitis (UC) and 
crohn’s disease (CD) is characterized with chronic relapsing 
conditions of inflammation through small intestine and colon, which 
accompanies inflammation response and epithelial injury 
(Szkaradkiewicz et al., 2009). Although both UC and CD are classified 
with IBD categories, they have distinct features with symptoms and 





partial inflammation through the gastrointestinal tracts (Loftus, 
2004), UC is typically characterized by occurring inflammation 
condition with ulceration mainly through the colon (Lepage et al., 
2011). Although these two types of IBD share manifold epidemiologic, 
therapeutic and clinical traits, CD and UC have distinct differences in 
the composition and population of gut microbiota. Especially in 
patients with CD, Faecalibacterium, Peptostreptococcaceae, 
Anaerostipes, Methanobrevibacter and Christensenellaceae genus 
are deficient in comparison with healthy controls and UC patients 
(Pascal et al., 2017). It has also been revealed that the proportion of 
Firmicutes are decreased, wheareas gammaproteobacteria are 
increased in CD and Enterobacteriaceae has speculated to be 
associated with the pathogenesis of UC patients (Li et al., 2012). A 
highlighted feature in microbiome level has shown that F. prausnitsii 
which is classified with C. leptum group has reduced abundance in 
both CD and UC (Sokol et al., 2009). In addition to recent study, 
examining biopsies of intestine and fecal samples from IBD patients 
and healthy controls demonstrated that alterations abundance of gut 
microbiota at the phylum level, such as Leuconostocaceae, 
Ruminococcacea and Enterobacteriaceae, while Clodstridium genus 
increased, but Roseburia which acts as a butyrate producer and 
phascolarctobacterium genus for producing succinate considerably 






2.2.3. IBD and gut immune response  
Cytokines have been considered as key factors of pathogenesis `of 
IBD in accordance with recent immunological and genetic studies by 
controlling inflammation response in gut and the related clinical 
indication of IBD. IBD patients have distinct characterization of altered 
cytokine patterns produced by immune cells from the lamina propria 
under the gut epithelial cells. Although there has been some attempts 
to treat IBD patients consuming recombinant anti-inflammatory 
cytokines including IFNβ, IL-10 or specific antibodies for 
suppressing pro-inflammatory cytokines such as TNF, only antibody 
specific binding TNF (infliximab) showed alleviating effects for 
crohn’s disease through clinical trials (Van Dullemen et al., 1995). 
TNF-α is a well-known proinflammatory cytokine produced by 
macrophages, monocytes, and T lymphocytes activated with immune 
response (Papadakis and Targan, 2000). Its expression in human 
macrophages was increased in colonocytes and macrophages in IBD 
patients (Stucchi et al., 2006) and high concentration of that in serum 
levels could be used to diagnose IBD as clinical and laboratory criteria 
of intestinal disease acitivity (Reimund et al., 1996). In addition, some 
kinds of pro-inflammatory cytokines, expecially TNF, have been 
observed to modify tight junction activity and to cause apoptosis of 
IECs (Su et al., 2013).  
Maintenance of epithelial integrity by proliferation and expansion 





inflammation response for enhancement of intestinal barrier function 
and treatment of the inflamed mucus layer in IBD (Neurath and Travis, 
2012). When the intestinal barrier function is impaired by pathogens, 
allergens or external elements such as diets or antibiotics, intestinal 
components and microbiota are easily translocated, which is known as 
the cause of chronic inflammation in IBD patients (Wallace et al., 
2014). However, in normal gut homeostasis condition, only some kind 
of gut bacteria could selectively translocate through tight junctions of 
the epithelial cell, this translocation can be used as a way of sampling 
for antigens and immune observation to maintain the host’s 















2.3. IBD and probiotics 
2.3.1. Probiotics  
Probiotics have been defined by various meanings until World 
Health Organization (WHO) has made a definition of probiotics in 
2002 (Azizpour et al., 2009). According to WHO, the term of 
probiotics represents “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the host.” 
which means they can survive in gastrointestinal environment and 
keep viability during storage and safety properties when ingested for 
human. Although there are many microorganism having health 
promoting effects, most studies have focused on examining only 
some bacterial genera, such as species of Lactobacillus, 
Enterococcus, Streptococcus and Bifidobacterium. However, some 
kinds of these genera, such as Enterococcus and Bacillus have 
increased concerns of their safety traits for human health (Hempel et 
al., 2011). There are several isolated strains of lactic acid bacteria 
conferring many health effects in clinical trials, including species of 
Lactobacillus plantarum 299v, L. rhamnosus GG, L. acidophilus La5 
and B. lactis Bb-12 (Bengmark, 2013).  
Probiotics have been related to many health benefits, 
fundamentally focused on the health promoting effects in 
gastrointestinal tract through several regulating mechanisms. 
Probiotic strains can replace harmful bacteria with harmless bacteria 





pathogenic bacteria by secreting antimicrobial compounds or short 
chain fatty acids (SCFAs) such as butyrate, lactate and acetate, which 
reinforce gut barrier function and are used by the colonocytes as the 
main source of energy. They have been also demonstrated immune-
modulating effects by stimulating immune cells and inducing cytokine 
production or increasing IgA secretion (Steidler, 2001). In addition 
to these benefits, some probiotic bacteria can improve the mucosal 
barrier by prevention and repair of mucosal damage led to pathogens, 
food antigens, or antibiotics (Saxelin et al., 2005). 
Apart from immunomodulation and improvement gut barrier 
function, they conduct various health improvement by reducing 
cholesterol, alleviating lactose intolerance, preventing diarrhea, 
inhibiting helicobacter pylori and treating allergy(Singh et al., 2011). 
 
2.3.2. Relationships between probiotics and IBD  
Potential mechanisms of health benefits for improvement and 
treatment of IBD symptoms have been explored through extremely 
many kinds of studies using animal models and clinical trials. 
Probiotics can be applied for exerting their prevention and treatment 
effects with three mechanisms of action.  
First of all, probiotics can inhibit domination of pathogenic bacteria 
in intestine by competing with nutrients and adhesion sites or 
secreting antimicrobial compounds. For instance, high adherence 





access and invasion of intestinal pathogens or external pathogens 
which could induce chronic and acute inflammation such as 
Helicobacter, Campylobacter, pathogenic Escherichia species (Allen 
et al., 2010). In addition to inhibition of pathogenic bacteria, 
probiotics could modulate the composition of the gut microbiota by 
interacting with specific pattern-recognition receptors including 
TLRs located on the surface or inner membrane of immune cells by 
inducing immune responses in the gut (Bouskra et al., 2008). 
Second mechanism includes regulation and development effects of 
some parts of the human GIT, such as mucus layer, epithelial cells, 
and GALT. The mucus layer, which is subdivided into outer layer with 
mucin molecules and inner mucin sublayer for restricting 
translocation of gut bacteria. Probiotics can exert the prevention 
effects of IBD by strengthening tight junction complexes such as 
occludin and claudin groups and promoting production of mucins 
(Sánchez et al., 2017).  
Finally, some probiotics have immunomodulating effects by 
regulating various cytokine production through gut immune cells, 
especially T regulatory cells associated with the maintenance of gut 
homeostasis and establishment of tolerance against the residing 








2.3.3. Probiotics products for IBD treatment 
On account of numerous studies involving the relationship 
between gut microbiota and IBD, probiotics with effects of modifying 
the gut flora have been suggested for treatment or alleviation of 
chronic intestinal inflammation. There have been various attempts to 
develop different preparation of probiotics including Lactobacillus 
rhamnosus GG, L. johnsonii LA1, E. coli  Nissle 197, and VSL#3 
either in animal models or in clinical trials, which are summarize in 
Table 1. VSL#3 is a probiotic product developed by Alfasigma Inc. 
from USA, which contains S. thermophilus, B. breve, B. longum, B. 
infantis, L. acidophilus, L. plantarum, L. casei and L. bulgaricus and 
has been demonstrated its beneficial effects by normalizing gut 
barrier function, reducing pro-inflammatory cytokines and alleviating 



















Mucosal Ig A↑ 
Similar endoscopic recurrence 
Intestinal permeability & clinical 
disease activity↓,  
(Malin et al., 1996) 
(Prantera et al., 2002) 
(Gupta et al., 2000) 
VSL #3 75 % still in remission and 
changed fecal flora 
(Venturi et al., 1999) 
 TLR-9 mediated anti-
inflammatory effect of DNA 
(Rachmilewitz et al., 
2004)  
 Improvement of recurrent colitis 







Improvement of IBD by 
downregulation of pro-
inflammatory cytokines (IL-6) 





Chapter 3. Materials and methods 
 
3.1. Isolation and identification of lactic acid bacteria 
3.1.1. Collection of traditional fermented foods 
The traditional fermented foods for isolating lactic acid bacteria 
were collected from Ganwon-do, South Korea. 52 samples of Kimchi, 
20 samples of Jeotgal, 4 samples of Makgeolli, 1 sample of 
Chenggukjang were prepared for this study (Table 2). After samples 
of collected fermented foods were transported within 4 hours, the 10 
g of samples were separated in 50 ml conical tubes and stored at 4 ℃ 
in refrigerator or at -80 ℃ in deep-freezer before proceeding 
isolation of lactic acid bacteria. 
 
Table 2. Origin of the samples for isolation of lactic acid bacteria (LAB) in 
this study. 
Sample 
Gangwon-do, South Korea 




Kimchi 27 · 13 ·12 52 
Jeotgal  9 · 11 · 20 
Makgeolli · 2 · 2 4 







3.1.2. Isolation of lactic acid bacteria 
After each fermented foods sample (1 g) was weighted, the sample 
was serially diluted 10-fold using 0.85 % NaCl solution (Sigma-
Aldrich, USA) and mixed well by hand. An amount of 0.1 ml of 0.85 % 
NaCl serial dilution were spread on de Man, Rogosa and Sharp (MRS) 
(Difco, USA) agar for selectively isolating lactobacilli, M17 (Difco, 
USA) with 10 % lactose (Difco, USA) agar for lactococci isolation. 
The inoculated MRS plates were incubated at 37 ℃ under anaerobic 
condition used an anaerobic chamber (Coy Laboratory products, 
AnnArbor, MI, USA) and M17 plates were incubated at 37 ℃ and 30 ℃ 
under aerobic condition for 48 h. After incubation, single colonies with 
different morphologies were collected and inoculated to same broth 
media. Inoculated MRS broth and M17 broth were incubated for 24 h 
at 37 ℃ under aerobic condition. Overnight incubated broth of isolates 
were streaked on plate count agar containing bromocresol purple (BCP) 
(Eiken chemical co., Ltd, Japan) to confirm single strains at 37 ℃ and 
30 ℃ aerobically for 24h. Subsequently, catalase test using 3 % 
hydrogen peroxide (H2O2) and gram staining (Becton, Dickinson and 
Company, USA) were done for screening LAB. Only catalase negative 
and gram positive isolates were selected and maintained at -80 ℃ in 










3.1.3. Resistance to low pH and bile salts 
Resistance to low pH Frozen isolates were activated by 
subsequently inoculation into MRS broth twice every 24 h for 
assessment of acid and bile tolerance of LAB. All strains were 
prepared in MRS broth for 18 h at 37 ℃. To examine survival of LAB 
strains under acidic condition, 50 ㎕ (1 %) of cultures were 
inoculated into 5 ml of MRS broth adjusted pH at 3.0 with 1 N HCl. 
The number of initial inoculum was counted immediately by drop 
plating on MRS agar. The inoculated samples were incubated at 37 ℃ 
under aerobic conditions for 2 h. After incubation, 0.1 ml of sample 
was transferred to 1 Ⅹ phosphate buffered saline (PBS) solution, 
and then serially diluted solution was spread on MRS agar by drop-
plating methods. The MRS agar plates were cultured for 24 h at 37 ℃. 
The colonies grown on MRS agar were counted and compared with 
initial counts (Yeo et al., 2016).  
Bile resistance To estimate bile tolerance of LAB, 50 ㎕ (1 %) of 
overnight cultures (18 h) were inoculated to 5 ml of MRS broth 
supplemented with 0.3 % bovine bile (Oxgall, Difco) or without bile 
as a control group simultaneously and incubated at 37 ℃ under 
aerobic conditions for 12 h. The treatment and control groups, each 
with a triplicate, were compared by measuring the optical density for 
detection of cell growth between two groups. The inoculated MRS 
plates were incubated at 37 ℃ aerobically for 24 h. The survival rate 





tolerance rate = OD600nm of 0.3 % oxgall MRS culture in treatment 
group/ OD600nm of MRS culture in treatment (Hassanzadazar et al., 
2012).  
 
3.1.4. Safety assessment 
Antibiotic Resistance Antibiotic susceptibility for selected 
antibiotics was tested by measuring minimal inhibitory concentration 
(MIC) and microbiological cut-off values (mg/L) of antibiotics were 
assessed based on the European Food Safety Authority guidelines 
(EFSA, 2012). Ampicillin, streptomycin, tetracycline, erythromycin, 
kanamycin, gentamycin, chloramphenicol were prepared for two fold 
dilutions with concentrations between 2 and 512 ㎍/㎖. Overnight   
(18h) cultures grown in LAB susceptibility medium (LSM) constituted 
by 90 % IsoSensitest broth (Oxoid, USA) and 10 % MRS broth were 
adjusted with optical density at 600 nm (O.D600nm) of 1 density 
(SPECTROstar nano, BMG LABTECH, Germany). A volume of 0.1 ml 
of the prepared antibiotics and 0.1 ml of bacteria cultures were 
inoculated to a 96-well microplates and diluted serially by two-fold 
and incubated at 37 ℃ for 24 h. The final concentrations were 
adjusted from 1 to 256 ㎍/㎖ and the MIC were evaluated as the 
lowest antibiotic concentration at which no growth of strains was 
observed (Leite et al., 2015). All strains for antibiotic susceptibility 
assay were conducted in triplicate.  





agar plates supplemented with 5 % (v/v) defibrinated sheep blood 
(KisanBio, Korea). The β-hemolysis was indicated by appearance of 
clear zone around the colonies. After the colony of each strain were 
streaked on the blood agar, the plates were incubated aerobically at 
37 ℃ for 48 h (Ji et al., 2015). Enterococcus faecalis ATCC 29212 
were tested as positive control.  
Biogenic amine production Analysis of biogenic amine production 
was conducted by method described as Bover-Cid and Hozapfel 
(1999). The isolates were streak on the decarboxylase media, 
followed by aerobic incubation at 37 ℃ for 4 days. Enterococcus 
faecalis ATCC 29212 were tested as positive control. Decarboxylase 
activity was detected with the color change from yellow to blue 
(Bover-Cid and Holzapfel, 1999). 
 
 
Figure 3. Sammary of the safety assessment methods of lactic acid bacteria. 
 
3.1.5. 16S rRNA sequencing 
The screened and selected strains were identified using amplified 





isolates was amplified by using universal primers, 27F (5'-AGA GTT 
TGA TCM TGG CTC AG-3') and 1492 R (5'-TAC GGY TAC CTT 
GTT ACG ACT T-3'). The PCR was conducted using thermal cycler 
(iCycler, Bio-Rad, Hercules, CA) at 95 ℃ for 3 min, 20 cycles of 
denaturation for 30 sec at 95 ℃, annealing for 30 sec at 55 ℃, and 
extension for 1 min at 72 ℃ and the final elongation for 5 min at 72 ℃. 
The PCR products was transferred to Macrogen corporation (South 
Korea) and analyzed by 16s rRNA gene sequencing. The analyzed 
sequences were compared with those collected in the GenBank 
database with the BLAST program (http://www.ncbi.nlm.nih.gov). 
 
3.1.6. Enzyme and fermentation test 
 API 50 CH and API ZYM (Bio-Merieux, France) were used to 
investigate carbohydrate fermentation and enzymatic profiles of 
selected isolates, respectively. The protocol of API kits was 
performed as manufacturer’s instructions. The activated cultures of 
isolates were centrifuged at 12,000 rpm, 4 ℃ for 5 min and washed 
twice with 0.85 % NaCl. Each of the strains was adjusted with OD600nm 
at 1 density. A volume of 65 ㎕ of each suspension was loaded in API 
ZYM kit wells respectively, and after the ZYM test strips were 
incubated after 4 h of incubation at 37 ℃, changes of color were 







3.2. Characterization and validation of LAB for 
functionality  
 3.2.1. Bacterial adhesion assay 
Cell culture The epithelial cell line of HT-29 derived from human 
colon adenocarcinoma were purchased from the Korean Cell Line 
Bank (KCLB, Seoul, Korea). The cells were grown in RPMI 1640 
medium (Gibco, USA) containing 10 % heat inactivated fetal bovine 
serum (FBS; Gibco, USA), L-glutamine (2 mmol l-1), 100 ㎍ 
streptomycin ml-1, 100 U penicillin ml-1, and 0.25 ㎍ amphotericin B 
ml-1 (Gibco, USA) at 37 ℃ in a 5 % CO2 atmosphere. To evaluate 
adhesion ability of LAB, HT29 cells were seeded at 1.0 Ⅹ 106 cells 
ml-1 in 12-well plates and incubated until fully differentiated for 10 
days by changing the media every two days. The cells were washed 
twice with preheated PBS and replaced with fresh non-supplemented 
RPMI for 2 h prior to the assay.  
Adhesion assay of LAB After harvesting the cells of LAB, 
overnight cultures of LAB strains were suspended with preheated 
fresh RPMI 1640 media and adjusted to O.D600nm at 1.0 density 
(aaproximately 1 Ⅹ 108 cfu ml-1). The 1 ml of each bacteria were 
inoculated to 12-well plates and incubated for 2 h at 37 in a 5 % 
CO2 atmosphere. Then, the non-adherent LAB were removed by 
washing with PBS two times and the HT29 cells and attached 
bacteria were lysed with 1 ml of 0.05 % Trypsin-EDTA (Gibco, 





serially (1 : 10) with PBS from the initial and using drop-plating 
method on MRS agar (Xu et al., 2009). Experiments were conducted 
in duplicate and relative adhesion rates were estimated by 
comparing with that of Lactobacillus rhamnosus GG. 
 
 3.2.2. Antimicrobial activity 
Disk diffusion assay For screening lactic acid bacteria strains 
which has potential inhibitory effects against specific major 
pathogens recognized as the cause of IBD and indicator strains, the 
paper disc method was carried out on a 1:1 mixture agar of brain 
heart infusion (BHI) and MRS (Karska-Wysocki et al., 2010). The 
pathogens and indicators were as follows: indicator strains, such as 
Listeria innocua, Listeria monocytogenesis, Staphylococcus aureus, 
Pseudomonas aeruginosa and Enterococcus faecalis and pathogens 
known as pathogenesis of IBD including Helicobacter pylori, 
Campylobacter coli, Campylobacter jejuni, and Escherichia coli. 
Overnight cultures of each strain were adjusted into OD600nm at 1 
density. 100 ㎕ of the bacteria cultures were inoculated and spread 
with sterilized cotton swab on the agar media. The paper disks (6mm; 
oxoid, USA) were placed on the BHI and MRS mixture agar plates. 
10 ㎕ of LAB cultures that probably have antibacterial activity were 
inoculated on the each disk. Inhibitory zone of LAB strains against 
microaerophilic bacteria strains were checked after 72 hour 





system (CampyGen, Oxoid) at 37 ℃. For assessing antimicrobial 
activity against indicator strains, the inoculated agar plates were 
incubated aerobically for 24 h at 37 ℃. The inhibitory effects were 
determined by measuring the diameters of inhibition zones. 
Agar well diffusion assay All pathogens and LAB strains were 
propagated overnight in BHI broth and MRS broth, respectively. The 
pathogen strains were centrifuged for 10 min at 12,000 rpm and 
suspended twice with PBS, and then the bacteria were adjusted to 
OD600nm of 0.2. A volume of 100 ㎕ of each pathogen culture was 
combined with 4 mL of LB (Difco, USA) soft agar (0.7 %) and poured 
onto LB agar plates. After the plates were dried for 30 min, wells was 
made on plate with sterile pipet. The 100 ㎕ overnight cultures of 
LAB isolates were inoculated in the wells. The microaerophilic 
bacteria plates were co-incubated for 72 h at 37 ℃ under 
microaerophilic conditions and indicator strains were co-incubated 
aerobically for 24 h at 37 ℃. The inhibition activity was determined 
by measuring the diameters of inhibition zones (Balouiri et al., 2016). 
ATP assay To determine antimicrobial activities of LAB 
supernatant against specific major pathogens causing IBD, 
intracellular adenosine triphosphate (ATP) of Helicobacter pylori, 
Campylobacter coli, Campylobacter jejuni, and Escherichia coli 
strains was measured. The pathogenic bacteria were prepared 
overnight and harvested by centrifugation 10,000 Ⅹ g, 4 ℃ for 8 





OD600nm values of 1 density. BacTiter-Glo reagent which is an ATP-
dependent luciferase-luciferin reagent mixture (Promega Inc., USA) 
was used in this study for measuring intracellular ATP contents. 50 
㎕ of pathogenic bacteria and each LAB supernatant was added to 
opaque 96 well plate, respectively, and then 100 ㎕ of the reagents 
was loaded to each well without light. After incubation for 5 min at 
37 ℃ for lysing the bacteria and triggering the enzymatic reaction, 
the emission of photons was assessed with luminometer (SpectraMax 
M4 Microplate/Cuvette Reader, Molercular Devices, USA) 
(Schweinitzer et al., 2008). 
 
3.2.3. Anti-inflammatory effects 
Culture of RAW 264.7 cells and HT-29 cells RAW 264.7 cell line 
of murine macrophages were obtained from the Korean Cell Line 
Bank (KCLB, Seoul, Korea). The cells were cultivated in Dulbecco’s 
modified Eagles medium (DMEM, Gibco, USA) supplemented with 10 % 
heat inactivated FBS, L-glutamine (2 mmol l-1), 100 ㎍ 
streptomycin ml-1, 100 U penicillin ml-1, and 0.25 ㎍ amphotericin B 
ml-1 (Gibco, USA) at 37 ℃ in a 5 % CO2 atmosphere. HT29 cell line 
were cultured with complete DMEM and seeded in 24-well plates at 
a concentration of 1.0 Ⅹ 105 cells ml-1 for 7 days at 37 ℃ in a 5 % 
CO2 atmosphere until fully confluence for assessing 
immunomodulation effects of LAB. 





seeded at 1 Ⅹ 105 cells ml-1 in 24-well plates and stabilized for 2 h. 
For stabilization of the cells, overnight cultures of LAB were 
centrifuged and the cell pellet were washed with PBS two times and 
adjusted with OD600nm at 1.0 density. The bacteria were heated for 15 
min at 110 ℃ to remove activity of bacteria, and then the cells were 
stimulated with 900 ㎕ of lipopolysaccharides (LPS, 1 ㎍/ml; 
sigma-aldrich, USA) and 100 ㎕ of heat-killed LAB for 48 h. The 
incubated cells were centrifuged at 600 Ⅹ g, 4 ℃ for 10 min and the 
cell supernatant were transferred to new tubes. The measurement of 
Nitric oxide (NO) concentration was estimated by using the Griess 
reagent (Promega Inc., USA) as the manufacture’ s instruction. 
After mixing the cell supernatant and griess reagent with same 
volumes, the mixture was incubated for 10 min at room temperature 
and absorbance at 540 nm was determined by a microplate reader 
(SpectraMax M4 Microplate/Cuvette Reader, Molercular Devices, 
USA). The concentration of NO was calculated by comparing to a 
standard curve (Lee et al., 2008). 
Enzyme-linked immunosorbent assays (ELSIA) The HT-29 
cells were plated at 1 Ⅹ 105 cells/well and incubated until fully 
confluence condition by changing media every two days. 24 h before 
coculture, media was changed with DMEM containing 5 % heat 
inactivated FBS and no antibiotics solution. The LAB were propagated 
by subculturing twice and adjusted with OD600nm at 1.0 (aaproximately 





were incubated with 10 ng ml-1 of human tumor necrosis factor-α 
(TNF- α; PeproTech, INC., USA) and 100㎕ of LAB strains for 6 h, 
the cell supernatants were collected and centrifuged at 13,000 Ⅹ g 
at 4 ℃ for 5 min. The cytokines of IL-8 in the supernatants were 
determined by ELISA as the manufacturer’s protocols (Koma Bio-
Tech, Seoul, Korea) and measured by the microplate reader 
(SpectraMax M4 Microplate/Cuvette Reader, Molercular Devices, 
USA))at 450 nm (Shi et al., 2017). 
 
3.2.4. Evaluation of tight junction integrity 
Cell cultures and bacterial administration Caco-2 cell line 
obtained from Korean Cell Line Bank (KCLB, Seoul, Korea) was 
originated from a human colonic adenocarcinoma and used between 
passages 40-60 for all experiments. Cells were maintained in 
minimal essential medium (MEM; corning Costar Corporation, USA) 
supplemented with 20 % heat inactivated FBS, 2 mM L-glutamine l-
1, 100 U penicillin ml-1, and 100 ㎍ streptomycin ml-1. Lactic acid 
bacteria cultures were prepared by adjustment of OD600nm at 0.1. 
TNF- α (10 ng ml-) were treated on caco-2 cell monolayers and 
the cells were incubated for 24 h. After incubation with TNF- α, the 
1 ml of bacterial suspensions with fresh MEM media were inoculated 
on the cell monolayers and co-cultured for 6 h.  
RNA isolation and reverse transcription The caco-2 cells 





centrifugation at 1,000 Ⅹ g for 3 min. RNA of the cells were treated 
and extracted with AccuZolTM (Bioneer, USA) according to 
manufacturer’s protocol. For cDNA synthesis, the ReverTra Ace® 
qPCR RT Master Mix with gDNA Remover kit (TOYOBO, Japan) was 
used following the manufacturer’s instruction. After mixing every 
reagents of the kit, amplification was conducted using a C1000 Touch 
thermal cycler (Bio-Rad, USA). It was incubated at 37 ℃ for 15 min, 
at 50 ℃ for 5 min and at 98 ℃ for 5 min. The synthesized cDNA 
was stored at 4 ℃ before the experiment.  
Quantification of mRNA expression using real-time PCR 
(qRT-PCR) qRT-PCR was carried out using TOPrealTM qPCR 2Ⅹ 
PreMIX (SYBR Green with low ROX) kit (Enzynomics, Korea) 
according to manufacturer’ s protocol. Oligonucleotide sequences 
for ZO-1 (TJP1), claudin-1 (CLDN1), occludin (OCLN) and β-
actin used to analyze tight junction proteins expression are indicated 
in Table 3. (Sanchez-Muñoz et al., 2008) 
Table 3.  Primers of RT-PCR for analyzing tight junction proteins 
expression. 
Gene Forward primer Reverse primer 
Product size 
(bp) 
CLDN1 GTGGTTGGCATCCTCCTG AATTCGTACCTGGCATTGACTGG 232 
TJP1 CAAGATAGTTTGGCAGCAAGAGATG ATCAGGGACATTCAATAGCGTAGC 182 
OCLN TCAGGGAATATCCACCTATCACTTCAG CATCAGCAGCAGCCATGTACTCTT 189 






3.3. Validation of selected strains in in vivo model  
3.3.1. Mice and experimental design 
 8 week-old female C57BL/6 mice were randomly distributed in 6 
groups and housed at cages in the animal facilities under the specific 
pathogen free environment and standard conditions (50-60 % 
humidity, 12-h dark/12-h light cycles). To induce acute colitis, 2.5 % 
dextran sulphate sodium (DSS, MW 36,000-50,000; MP Biomedicals, 
USA) was added into the drinking water for one day, then the 
concentration of DSS was elevated with 5 % for two days. After 
constructing IBD model by adding DSS into the drinking water for 
three days, mice were randomly allocated to three groups for testing 
the probiotic effects of selected strains. The mice of LGG group (9 
mice) were injected with L. rhamnosus GG by oral administration 
every day, whereas the mice of HS-2 (9 mice) and NG-4 groups (9 
mice) were gavaged with Weissella cibaria HS-2 and Pediococcus 
acidilactici NG-4, respectively every day for two weeks. After 2 
weeks of feeding, animals were sacrificed by injecting tribromoethanol 
overdose. The animal experiment in this study were approved by the 
Institutional Animal Care and Use Committee of Seoul national 








Figure 4. Time schedule for the study of in vivo IBD model.  
 
Table 4. Experimental design of the groups and LAB treatment.  










HS-2 3 3 Weissella cibaria HS-2 (3.7±1.4)Ⅹ108 14 





3.3.2. Probiotic preparation 
W. cibaria HS-2 and P. acidilactici NG-4 selected from in vitro 
study and L. rhamnosus GG (LGG) which is a well-known 
commercial strain, were cultivated in MRS broth for 18 h at 37 ℃. 
After bacterial cells were harvested by centrifugation at 14,000 Ⅹ g 
for 7 min and washed twice with PBS. The LAB cells were prepared 







3.3.3. Sampling of fecal, serum and colons 
The fecal samples were collected once a week during the 
experiment period and After sacrifice on day 17, the samples were 
collected directly from the large intestine and immediately moved into 
Eppendorf tubes and stored at -80 ℃. Genomic DNA from the fecal 
samples was extracted by using the commercial FastDNA Spin Kit 
for Soil (MP biomedicals, USA) according to the manufacturer’s 
protocols. The blood was harvested by vein puncture in silca coated 
tubes (BD, USA) for serum determination. After the blood samples 
were left for 30 minutes at room temperature for allowing to clot, the 
serum was collected by centrifugation (4000 Ⅹ g, 4 ℃, 10 min) and 
stored at -80 ℃ until analyzed by using ELISA kits. The 
experimental mice were sacrificed and the colon samples were 
obtained by dissecting sacrificed mice and the samples were directly 
treated with AccuZolTM (Bioneer, USA) and stored at -80 ℃ until 
analyzed. Frozen tissue samples were homogenized by using mini 
homogenizer and stored at -80 ℃ until extracting RNA from the 
samples. 
 
3.3.4. Evaluation of colitis 
For evaluating colitis during consumption of DSS, animals were 
checked daily for weight, water/food consumption, stool consistency 
and existence of total blood in feces. The disease activity index (DAI) 





none, (1 point = none, 2 point = 1%–2% weight loss, 3 points = 2%–
5 % weight loss, 4 points = 5 %–10 % weight loss and 5 points = more 
than 10% weight loss); b) stool consistency/diarrhea (1 point= normal, 
3 points = loose stools, 5 points = watery diarrhea); c) bleeding (1 
points = no bleeding, 3 points = slight bleeding, 5 points = gross 
bleeding) as described by Murthy et al. (1993). 
 
3.3.5. Measurement of cytokines 
The cytokines of TNF-α, IL-10 and IL-17 and in the collected 
serum samples were determined by using ELISA kits according to 
the manufacturer’s protocols (Koma Bio-Tech, Seoul, Korea) and 
measured by the microplate reader (SpectraMax M4 
Microplate/Cuvette Reader, Molercular Devices, USA)) at 450 nm 
(Shi et al., 2017). The levels of detected cytokines were calculated 
from the standard curves. 
 
3.3.6. RNA Extraction and Real-time PCR 
For RNA extraction from the colon tissue samples, total RNA was 
isolated using AccuZolTM (Bioneer, USA) according to manufacturer’s 
protocol. For cDNA synthesis, the ReverTra Ace® qPCR RT Master 
Mix with gDNA Remover kit (TOYOBO, Japan) was used following the 
manufacturer’s instruction. After mixing every reagents of the kit, 
amplification was conducted using a C1000 Touch thermal cycler 





min and at 98 ℃ for 5 min. The synthesized cDNA was stored at 4 ℃ 
before the experiment. The relative expression of tight junction 
proteins in colon was detected by qRT-PCR which was carried out 
using TOPrealTM qPCR 2Ⅹ PreMIX (SYBR Green with low ROX) kit 
(Enzynomics, Korea) according to manufacturer’s protocol. 
Oligonucleotide sequences for ZO-1 (TJP1), claudin-1 (CLDN1) and 
GAPDH which was used to analyze tight junction proteins expression 
are indicated in Table 5. 
 
Table 5. Primers of RT-PCR for analyzing tight junction proteins expression. 
Gene Forward primer Reverse primer 
Product size 
(bp) 
CLDN1 TATGACCCCTTGACCCCCAT TTGTTTTCCGGGGACAGGAG 127 
TJP1 GCAGACTTCTGGAGGTTTCG CTTGCCAACTTTTCTCTGGCAAC 194 















Table 6. 16S rRNA gene targeted group specific primers of RT-PCR for 
analyzing intestinal bacterial flora of mouse feces. 
Gene Forward primer Reverse primer 
Product size 
(bp) 
Weissella cibaria TTGATTGACGTAGAACCTGAT TTC GGT GCT AGT TCT TCA ATA 596 
Akkermansia muciniphila CAGCACGTGAAGGTGGGG CCTTGCGGTTGGCTTCAGAT 327 
Enterobacteriaceae CATTGACGTTACCCGCAGAAGA CTCTACGAGACTCAAGCTTGC 195 
Lactobacillus spp. TGGATGCCTTGGCACTAGGA AAATCTCCGGATCAAAGCTTACTTAT 92 
Bifidobacteria spp. CGCGTCYGGTGTGAAAG CCCCACATCCAGCATCCA 244 
Pediococcus spp. GGACTTGATAACGTACCCGC GTTCCGTCTTGCATTTGACC 449 
Universal primer sets CCTACGGGAGGCAGCAG GGACTACHVGGGTWTCTAAT 450 
 
The relative expression of the intestinal bacterial flora were 
analyzed by qRT-PCR by detecting 16S rRNA gene targeted group 













Chapter 4. Results 
 
4.1 Isolation and identification of lactic acid bacteria 
4.1.1. Lactic acid bacteria isolation 
77 samples of Korean traditional foods were assembled from 
mainly the province of Gangwon, South Korea. Total 399 isolates 
were obtained from the samples by using culture dependent methods 
with selective media, such as MRS medium and all isolates were 
confirmed to be LAB by conducting catalase test, gram staining and 
assessing and physiological traits. 
 
Table 7. The number of isolates obtained from Korean fermented foods. 
Sample No. of samples No. of isolates 
Kimchi 52 ·283 
Jeotgal 20 ·68 
Makgeolli 4 42 
Cheonggukjang 1 ·6 










4.1.2. Screening and identification of LAB with probiotic 
properties 
For screening every isolate from the samples with fast and simple 
ways, 399 isolates were sorted out for resistance rate in condition of 
acid and bile salt. 38 isolated strains were selected with higher 
relative survival rates when compared to those of Lactobacillus 
rhamnosus GG, which was used as a standard reference culture in 
this study and commercial lactic acid bacteria.  
Antibiotic resistance properties of the selected isolates were 
determined by MIC of each type of antibiotics which were 
recommended to assess susceptibility according to microbiological 
breakpoints of European Food Safety Authority (EFSA). 7 isolates of 
the selected bacteria were excluded by determining resistance of 
some antibiotics and cut off by the microbiological breakpoints 
4 isolates of 21 LAB which were selected by demonstrating traits 
antibiotic susceptibility based on criteria of EFSA were shown β-
hemolytic activity, known as complete hemolysis by breaking down 
of red blood cells in blood agar and producing clear zone around the 
cultivated colonies.  
4 isolates of the screened bacteria by demonstrating negative 
hemolysis activity were characterized with expressing properties of 
biogenic amine production.  
Finally, 23 isolates of LAB were examined and selected for 





antibiotic susceptibility, hemolytic activity and biogenic amine 
production property.  
 
 
Figure 5. The examples of the result of hemolytic activity and biogenic amine 
production of test bacteria (Positive reaction of β-hemolytic activity, left; 
L. sakei G7, production of biogenic amin, right; E. faecium M0h-3 ). 
 
Selected 23 strains with evaluation of in vitro intestinal survival 
rate and safety features for human use were identified by analyzing 
16s rRNA gene sequence using BLAST database. Only 10 strains 
were selected for further studies by the criteria on the basis of 
considering tolerance properties in acid and bile environments and 
species diversity of identified strains (Table 8). 
The identified strains include Enterococcus, Lactobacillus, 
Pediococcus, Weissella species which isolated from Kimchi and 





Table 8. Identification and characterization of 10 selected isolates. 
No 
16s rRNA sequence analysis 
(Closest known species) 
Strain Origin 
Catalase test Gram staining 
Morphology 
Culture conditiona 
(+/-) (+/-) Anaerobic Aerobic 
1 Enterococcus faecium M7k-1 Kimchi - + Cocci + + 
2 Lactobacillus brevis B4 Kimchi - + Rod + + 
3 Lactobacillus paracasei Mr-1 Kimchi - + Rod + + 
4 Lactobacillus plantarum M0u-3 Kimchi - + Rod + + 
5 Lactobacillus sakei RS6 Kimchi - + Rod + + 
6 Pediococcus acidilactici NG-4 Jeotgal - + Cocci + + 
7 Pediococcus pentosaceus B7 Kimchi - + Cocci + + 
8 Pediococcus pentosaceus HS-1 Jeotgal - + Cocci + + 
9 Weissella cibaria HS-2 Jeotgal - + Cocci + + 
10 Weissella hellenica WKC-4 Kimchi - + Cocci + + 





All of 10 selected strains evaluated to have tolerance ability 
to acidic conditions, pH 3. After incubation for 2 h in MRS medium 
which pH value is 3, the survival rates of M7k-1, B4, Mr-1 and 
WKC-4 strains showed significantly higher survivability 
compared to LGG, reference strains. The LGG as positive control 
were demonstrated as survival rate of 73.41 %. Though all 
strains including LGG tested in this study show low relative 
survival rates in MRS medium with 0.3 % (w/v) oxgall, eight 
strains of selected LAB except RS6 and WKC-4 showed 







Table 9. In vitro intestinal survival rate and minimum inhibitory concentrations (μg/ml) of antibiotics to selected lactic acid bacteria. 
Species Strains 
In vitro intestinal survival rate  Antibiotics susceptibility 
Bile tolerancea (%) Acid toleranceb (%)  AMP GEN KAN STR ERY TET CHL 
E. faecium M7k-1 64±4.64** 103.19±12*  2 32 256 8 <2 <2 <2 
L. brevis B4 67±14.25** 100.00±7**  <2 16 64 64 <2 <2 <2 
L. paracasei Mr-1 43±2.32** 122.16±26*  4 16 64 64 <2 <2 2 
L. plantarum M0u-3 36±5.71** 83.33±15  <2 4 32 4 <2 2 8 
L. sakei RS6 23±9.08 72.83±16  4 16 64 64 <2 4 4 
P. acidilactici NG-4 46±2.87** 107.84±29  4 4 64 64 <2 4 4 
P. pentosaceus B7 32±4.31** 73.68±24  4 16 64 64 <2 <2 4 
P. pentosaceus HS-1 39±3.32** 81.82±14  4 16 64 4 <2 4 4 
W. cibaria HS-2 42±4.29** 75.00±10  4 4 64 32 <2 8 2 
W. hellenica WKC-4 46±16.93 100.00±3**  2 16 256 16 <2 8 4 
L. rhamnosus GG 18±0.88 73.41±7         
Suggested breakpoint in accordance to the European Food Safety Authority (EFSA) 
Pediococcus  4 16 64 64 1 8 4 
Lactobacillus plantarum  2 16 64 64 1 32 8 
Lactobacillus paracasei  4 32 64 64 1 4 4 
Lactobacillus facultative heterofermentative  4 16 64 64 1 8 4 
Enterococcus faecium  2 32 1024. 128 4 4 16 
AMP, GEN, KAN, STR, ERY, TET, and CHL refer to ampicillin, gentamycin, kanamycin, streptomycin, erythromycin, tetracycline and chloramphenicol, respectively  
a Relative bile tolerance (%) in MRS media supplemented with 0.3 % (w/v) oxgall, 
b Bacterial cell survival rate (%) at pH 3.0 





4.1.3. Enzymatic and fermentation profiles 
The selected 10 LAB strains showed completely dissimilar 
patterns of fermentation which means that every isolates are identified 
as distinct strains even though B7 and HS-1 are classified with same 
species, Pediococcus pentosaceus. All strains are characterized with 



















Figure 6. Enzyme patterns and carbohydrate fermentation of selected LAB were assessed by API ZYM kit, and API 50 CHL, 
respectively. The biochemical properties are shown in a black-white color scale, where black represents positive activity and 





4.2. Characterization and validation of functionality 
4.2.1. Adherence ability to epithelial cells 
For evaluation of each adherence ability of 10 selected LAB, all 
experiments were conducted in 12 well plates with duplicate. The 
relative adhesion rates of selected bacteria were evaluated by 
comparing with LGG as a control strain using HT-29 epithelial cell 
line. L. brevis B4 strains showed unequaled adhesion ability higher 
than almost 7-fold to intestinal epithelial cell compared with LGG. In 
addition, E. faecium strain M7k-), L. paracasei Mr-1, P. acidilactici 
NG-4, P. pentosaceus B7, W. cibaria HS-2 has significantly higher 
adhesion rates than control strain. Strain of HS-1 showed similar 
adhesion ability when compared with LGG.  
 
Figure 7. The relative adhesion rate of lactic acid bacteria strains on HT 29 
cells. Relative adherence was represented by a fold change compared with 
that of LGG. The data represent the means and standard errors of duplicates. 









































4.2.2. Antimicrobial activity 
The objective of high speed screening LAB and confirmation with 
antimicrobial activity, two kinds of methods were used in this study. 
Disk diffusion assay were used for screening LAB fast and simply 
and the degree of antimicrobial activity were assessed by measuring 
length of clear zone around the well using agar well diffusion method.  
 
Figure 8. The examples of result for disk diffusion assay (left) and agar well 
diffusion assay (right). 
 
The antimicrobial activity of the disk diffusion of LAB were 
assessed against food-born pathogen indicators and major pathogens 
in pathogenesis of IBD except helicobacter pylori and campylobacter 
coli as these pathogens didn’t grow on the agar plates with 1:1 
mixture of MRS and BHI medium. Every selected strains showed 
antagonistic effects against campylobacter coli, Staphylococcus 






Table 10. The assessment of antimicrobial activity by disk diffusion assay. 
Species Name 
Existence of the zone of inhibitiona 
SA K88 EF LM LI PAO1 C. coli 
E. faecium M7k-1 + + + + + + + 
L. brevis B4 + + + + + + + 
L. paracasei Mr-1 + + + + + + + 
L. plantarum M0u-3 + + + + + + + 
L. sakei RS6 + + + + + + + 
P. acidilactici NG-4 + + + + + + + 
P. pentosaceus B7 + + + + + + + 
P. pentosaceus HS-1 + + + + + + + 
W. cibaria HS-2 + + + + + + + 
W. hellenica wkc-4 + + + + + + + 
L. rhamnosus LGG + + + + + + + 
C. coli; Capmpylobacter coli KTCC 15212, K88; Escherichia coli K88 SA; Staphylococcus aureus 
ATCC 25922. EF; Enterococcus faecalis ATCC 29212, LI; Listeria innocua ATCC 33090, LM; 
Listeria monocytogenes KCTC 13064, PAO1; Pseudomonas aeruginosa PAO1 
a +, > 1cm; w, < 1cm; -, no clear zone 
 
The results of antimicrobial activity for LAB cultures on growth of 
pathogens were evaluated by the agar well diffusion assay (Table 11). 
Almost every LAB strains have antimicrobial activities against major 
pathogen groups in the pathogenesis of IBD and food-born pathogen 
indicator groups, except the strain of L. brevis B4. As it’s shown 
almost every strains except B4 has antimicrobial activity by forming 
clear zone around the well, ranging from 1.16 cm to 2.57 cm. L. 
paracasei Mr-1 has the strongest antimicrobial activities among the 





Table 11. Diameter of the zone of inhibition against pathogens. 
Species Name 
Major pathogens in the pathogenesis of IBDa (mm)  Foodborne pathogen indicators
b (mm) 
C. coli HP CJ K88  SA EF LM LI PAO1 
E. faecium M7k-1 1.76±0.09 1.42±0.1 1.63±0.15 1.81±0.15 
 
1.47±0.02 1.6±0.2 1.49±0.06 1.51±0.08 1.43±0.07 
L. brevis B4 1.62±0.12 - - 1.76±0.11 
 
1.53±0.09 - 1.71±0.13 1.59±0.09 1.76±0.11 
L. paracasei Mr-1 2.5±0.25 1.5±0.07 1.91±0.08 1.92±0.09 
 
1.71±0.05 1.29±0.04 1.63±0.01 1.58±0.05 1.75±0.06 
L. plantarum M0u-3 2.1±0.09 1.3±0.13 1.74±0.18 1.75±0.09 
 
1.46±0.14 1.16±0.03 1.37±0.1 1.64±0.04 1.43±0.1 
L. sakei RS6 1.98±0.07 1.46±0.13 1.62±0.13 1.74±0.17 
 
1.48±0.02 1.21±0.03 1.46±0.12 1.57±0.09 1.29±0.03 
P. acidilactici NG-4 2.05±0.19 1.54±0.05 2.28±0.13 1.9±0.11 
 
1.5±0.04 1.44±0.12 1.43±0.13 1.54±0.05 1.88±0.08 
P. pentosaceus B7 2.01±0.13 1.56±0.06 1.85±0.08 1.67±0.03 
 
1.39±0.1 1.32±0.01 1.5±0.16 1.69±0.12 1.67±0.03 
P. pentosaceus HS-1 1.99±0.08 1.67±0.07 1.82±0.13 1.56±0.17 
 
1.38±0.07 1.3±0.08 1.39±0.05 1.47±0.06 1.56±0.17 
W. cibaria HS-2 1.8±0.15 1.74±0.21 1.69±0.11 1.83±0.13 
 
1.48±0.07 1.2±0.08 1.44±0.12 1.59±0.03 1.39±0.09 
W. hellenica WKC-4 1.58±0.15 1.79±0.17 2.19±0.18 1.69±0.08 
 
1.41±0.09 1.56±0.06 1.33±0.11 1.55±0.07 1.9±0.03 
L. rhamnosus GG 2.57±0.19 1.58±0.1 1.72±0.16 1.72±0.18 
 
1.7±0.04 1.41±0.15 1.5±0.04 1.45±0.05 1.79±0.12 
a C. coli; Capmpylobacter coli KTCC 15212, HP; Helicobacter pylori KTCC 12083, CJ; Campylobacter jejuni subsp. Jejuni ATCC 33560, K88; Escherichia coli K88  
b SA; Staphylococcus aureus ATCC 25922, EF; Enterococcus faecalis ATCC 29212, LI; Listeria innocua ATCC 33090, LM; Listeria monocytogenes KCTC 13064, PAO1; Pseudomonas 






Figure 9. Measurements of intrabacterial ATP levels in the presence of 
target LAB strains. (A) Escherichia coli K88 (B) Helicobacter pylori ATCC 
12083 (C) Campylobacter coli KTCC 15212 (D) Campylobacter jejuni 
subsp. jejuni ATCC 33560. The data represent the means and standard 
errors of duplicates. Significance is indicated as follows; *P ≤ 0.05, **P≤ 
0.01, ***P ≤ 0.001. 
 
To evaluate the antimicrobial activity against main pathogens 
known as causing IBD, level of ATP produced from pathogens using 
bioluminescence assay was measured by the amount of relative light 
unit (RLU) which can be transformed into the RLU/mole of ATP. 
The RLUs of Escherichia coli K88 was significantly suppressed 
by the strains of M7k-1, Mr-1, NG-4, B7 and HS-2 compared to 





inoculating any LAB cultures, whereas LGG, M0u-3, RS6 and WKC-
4 cultures didn’t express inhibitory effects. The strain of HS-1 was 
the most powerful inhibition effects against Escherichia coli among 
the tested LAB (Figure 9 (A)). As shown in the figure 9 (B) which 
was measured for inhibition effects of Helicobacter pylori, almost 
every strains determined to have antimicrobial effects except B4 
strain. HS-1 significantly repressed the level of ATP and showed 
the strongest inhibition effects against Helicobacter pylori. The level 
of RLUs detected from Campylobacter coli was reduced by most LAB 
except M7k-1, B4 and RS6 and HS-1 strain also expressed the 
lowest level of RLUs, which has the most powerful inhibition effects 
(Figure 9 (C)). Although the results of other pathogen species by 
measuring intrabacterial ATP showed significant reduction effects, 
the results of Campylobacter jejuni didn’t expressed significant 












4.2.3. Anti-inflammatory activity 
 
Figure 10. Anti-inflammatory effects of heat-killed lactic acid bacteria in 
LPS (1 ㎍/ml) induced RAW 264.7 murine macrophage cells. The 
concentration of nitrile production was determined by calculating standard 
curve. Values are mean ± S.D of triplicates for each group. * P < 0.05, ** P 
<0.01, compared with treatment of only LPS. 
 
To examine the effects of selected lactic acid bacteria, 10 ng/ml 
of LPS was treated to 264.7 cells for 48 h to induce inflammation and 
NO production. 5 strains of 10 selected bacteria have shown the 
inhibition effects of NO production induced by LPS. E. faecium M7k-
1 was evaluated to have immune-regulating effects by significantly 
suppressing NO production compared to LGG and other strains. 























inflammatory effects compared with the positive control treated only 
LPS (Figure 10). 
 
 
Figure 11. Attenuation effects of TNF-α (10 ng/ml) mediated suppression 
of IL-8 production for 6 hours by co-incubation with selected lactic acid 
bacteria in HT-29 cells. Supernatant were harvested for IL-8 ELISA. 
*p<0.05, **p<0.01 by using t-test analysis. 
 
As shown in Fig. 11 which is the result of measuring IL-8 
production by ELISA, there was a significant regulating effects for 
secretion of IL-8 in TNF-α activated HT-29 cells by the strains of 
NG-4, HS-2 and WKC-4 compared to the treatment group of only 

































4.2.4 Evaluation of tight junction integrity  
 
 
Figure 12. Tight junction-related mRNA gene expressions by treatment of 
two selected lactic acid bacteria in TNF-α (10 ng/ml)-induced Caco-2 
monolayer. (a) Occludin (b) Zonula occludens-1 (c) Claudin-1. The 
monolayers were stimulated with TNF-α, and then incubated for 24 h. After 
24 h, LAB (O.D600nm = 0.1) were added on the cells, and incubated for 6 h. 
Data are expressed as mean ± SD. of triplicate experiments. *P<0.05, 
*P<0.01; Mock versus TNF- α, #P<0.05, ##P<0.01, ### P <0.001; LAB 







As shown in Fig. 12, the changes in the expression of tight junction 
proteins genes were characterized by performing quantitative RT-
PCR (qRT-PCR) analysis. TNF-α treatment caused significant 
decrease in mRNA gene expressions of all kinds of tight junction 
proteins in caco-2 monolayers. The administration of HS-2 strain 
significantly increased the occludin and claudin-1 mRNA expression 
after 24 hours, whereas the treatment of NG-4 strain significantly 

















4.3. Validation of selected strains in in vivo model 
4.3.1. Evaluation of colitis 
 
 
Figure 13. Evaluation of DSS-induced colitis. 5 % DSS were added in the 
drinking water for 3 days, and then water without DSS in all groups. (a) Time 
schedule of DSS treatment, (b) body weight and (c) average feed intake 
during administration of DSS, (d) photographs of fecal samples on day 3 of 
DSS administration and (e) disease activity index on day 0 and day 3 of DSS 
treatment. Vertical columns and error bars represent mean ± SD. *p<0.05 







Figure 14. Lactic acid bacteria ameliorates DSS-induced colitis in mice. In 
parallel, they were administrated daily LGG, HS-2 or NG-4 intragastrically 
for 14 days. (a) Time schedule of LAB treatment, (b) Body weight, (c) 
Average feed intake,(d) Disease activity index, (e) Survival rate for 17 
days (f) Photographs of fecal samples on day 7 and day 14 during LAB 
administration. Vertical columns and error bars represent mean ± SD. 






The body weight of animals didn’t show any changes over three 
days of observation, whereas average feed intake showed significant 
reduction during DSS administration over same time. Though the 
body weight changes were not observed during the 3 day period of 
DSS treatment, the photographs of feces on the last day of DSS 
treatment and the results of disease activity index represented that 
animal models of intestinal colitis established well during 3 days of 
DSS treatment (Figure 13). 
Though all groups of LAB treatment didn’t show any body weight 
changes for 14 days, the photographs of feces on 7 day and 14 day 
of LAB treatment exhibited clearly reduced bleeding and diarrhea. 
The administration of LAB for 14 days exhibited significant increase 
of average feed intake and disease activity index in NG-4 group. 
HS-2 and NG-4 groups showed better survival than LGG group. 
Disease activity indexes (DAI) in every LAB groups displayed a 











4.3.2. Colon length 
 
 
Figure 15. Colons of mice on day 14 of DSS-induced colitis in LGG (n=3), 
HS-2 (n=3) and NG-4 (n=3) groups. (a) Photographs of dissected colons 
on day 14 of LGG, HS-2 or NG-4 strain administration after inducing colitis 
by treatment of DSS. (b) Colon length in mice on day 14. Vertical columns 
and error bars represent mean ± SD. *p<0.05 versus LGG group by using 
t-test analysis. 
 
Markedly less reduction of the colon length was evident in the both 






4.3.3. Analysis on cytokine profile 
 
Figure 16. Serum levels of Cytokines in LGG, HS-2 and NG-4 strain group. 
(a) IL-10 (b) IL-17. Vertical columns and error bars represent mean ± 
SD. *p<0.05 by using t-test analysis. 
 
To investigate the attenuation effects of the selected lactic acid 
bacteria in DSS models, we analyzed serum cytokine profiling in 
TNF-α, IL-10 and IL-17. The production of TNF-α which is a 
typical pro-inflammatory cytokine was not changed significantly in all 
groups. Levels of IL-10, well-known anti-inflammatory cytokine, 
was significantly increased in NG-4 group after treating LAB for 14 
days. Significant reduction of IL-17 levels was observed in LGG and 





4.3.4. Microbiology analysis of mouse feces 
 
Figure 17. Relative bacterial quantitation in fecal samples at day 0 and at day 
14 as determined by qPCR. (a) Lactobacillus spp. (b) Weissella spp. (c) 
Pediococcus spp. (d) Bifidobacteria spp. (e) Akkermansia muciniphila (f) 
Enterobacteriaceae. Differences with in groups (day 0 and day 14) were 








DSS-induced colitis was related to total alterations in the fecal 
microbiota. Levels of Lactobacillus have a tendency to increase in 
both HS-2 and NG-4 group as well as significantly increased in the 
animals in the NG-4 group compared to LGG group at day 14. HS-
2 group are shown to have higher levels of Weissella spp. than LGG 
group at day 14. NG-4 group are seen to be similar levels of 
Pediococcus spp. at day 14 whereas the levels of that was 
significantly decreased at day 0 compared to LGG group, which 
means that the amounts of Pediococcus spp. have estimated to 
increase due to the consumption of NG-4 strain. In both probiotic 
group, levels of Bifidobacterium were increased after 14 days 
compared to the LGG control group. No significant differences were 
seen in levels of Akkermansia muciniphila. Though the levels of 
Enterobacteriaceae were not significantly varied in both LAB group 
at day 14, they have a tendency to decrease in NG-4 group at day 












4.3.5. Evaluation of tight junction integrity 
 
Figure 18. Colonic expressions of tight junction proteins. Quantitative real 
time PCR for determination of relative mRNA gene expression (a) Claudin-
1, (b) Zonula occludens-1 (ZO-1) after 14 days of LAB treatment. *p<0.05, 
**p<0.01 compared with LGG group by using t-test analysis. 
 
Quantification of tight junction proteins (claudin-1 and ZO-1) 
were conducted by real-time PCR. Significant increase of relative 
TJ proteins mRNA gene expression were seen when comparing the 





Chapter 5. Discussion 
 
Several studies have shown that a variety of factors and 
mechanisms, such as the actions of gut microbiota (Nell et al., 2010), 
regulatory T cells and cytokines playing a crucial role to modulate 
inflammation (Renz et al., 2012), and pathogenic infection including 
Helicobacter, Campylobacter, Salmonella species (Nell et al., 2010) 
are closely related to triggering IBD. As previously studied 
(Delcenserie et al., 2008), probiotics can healthfully modulate the 
composition of gut microbiota and the excessive immune response 
corresponding with the factors to cause IBD. Though many attempts 
to cure IBD by using probiotics have been recently attained 
(Damaskos and Kolios, 2008), there is still significant controversy 
regarding its effectiveness. Moreover, there is still no medication for 
treatment of IBD up to now according to Prisciandaro et al. (2009). 
Therefore, the objective of this study is to develop putative probiotics 
for alleviating intestinal inflammation with in vitro complicated 
methods by screening lactic acid bacteria isolated from Korean 
traditional fermented foods and to verify the attenuation effects of 
selected probiotics by using dextran sodium sulfate (DSS)-induced 
colitis models in vivo study. 





recognized as safe (GRAS) microbes, were isolated from 77 
fermented food samples with using selective medium. The first step 
of the study, isolated colonies of LAB were screened on the basis of 
acid and bile tolerance, that allow to evaluate survivability in the 
gastrointestinal tract and are key features to conserve health effects 
for their host in accordance with Dunne et al. (2001). Lactobacilli, 
Enterococcus and Pediococcus species generally showed resistance 
to low pH because of their functions to produce short chain fatty acids 
including lactic acid, acetate and butyrate, which agrees with previous 
studies (Pinto et al. 2006, Zago et al. 2011). It was assessed that 38 
LAB isolates were characterized with outstanding viability under 
acidic and bile salts conditions compared to reference strain, 
Lactobacillus rhamnosus GG, which is widely investigated of various 
probiotic properties (Näse et al., 2001).  
Safety assessments of the LAB isolates according to criteria 
suggested from EFSA were conducted as an essential stage for  
selection and validation of probiotics according to the study by 
Gueimonde and Salminen (2006). Owing to bacterial resistance to 
antibiotics is considered as a worldwide issue for both human and 
animal use with regard to a report of Yüceer and Özden Tuncer 
(2015), the safety assessment of LAB were conducted by antibiotic 





study, 23 isolates including Lactobacillus, Pediococcus, Weissella and 
Enterococcus spp. were evaluated to be safe even when consumed 
with high amounts, similar to other results of studies (Riboldi et al. 
2009, Toomey et al. 2010). Finally, 10 strains of LAB were selected 
for the further study for evaluating an adhesion ability to the epithelial 
cells, which is an important factor to prevent adhesion of pathogens 
from infections by competitively colonizing to intestinal mucosa in 
agree with Lee et al. (2008). It has been reported that the human 
colonic adenocarcinoma cell line HT-29 have been widely used to 
examine the adhesion rates of possible probiotic bacteria (Ayeni et 
al., 2011). Lactobacillus brevis B4 strain in this study showed 
exceptional adhesion rates and 6 strains (M7k-1, RS6, NG-4, B7 and 
HS-2) of 10 selected LAB performed similar adhesion values 
compared to LGG, signifying that these strains have great possibilities 
of colonization in in vivo intestinal environments. 
Selected LAB strains were evaluated with three main functions, 
including antimicrobial, anti-inflammatory activity and reinforcement 
ability of tight junction integrity in epithelial cells, to validate 
alleviating effects of intestinal chronic inflammation, based on the 
main factors of influencing IBD. By investigating antimicrobial 
activities using three different methods, most selected strains except 
Lactobacillus brevis B4, displayed inhibition effects against 





Campylobacter jejuni that possibly explain the cause of pathogenesis 
of IBD as well as foodborne pathogens according to reports of Hansen 
et al. (2010). Considering these results, we could anticipate health-
promoting effects of the probiotic candidates by preventing against 
recurrence of diarrhea, food poisoning, enteric colonization and 
dominance of the pathogens.  
To examine the anti-inflammatory effect of LAB in intestinal tract, 
nitric oxide (NO) and cytokine productions were determined by using 
microplate reader. NO production was measured by treating heat-
killed LAB on the lipopolysaccharide (LPS)-activated RAW264.7 
cells. It has been reported that NO is related to various immunological 
procedures such as host defence, immunoregulation and signal 
transduction and are importance mediators triggering IBD (Schoedon 
et al. 1995). Dijkstra (2004) reported that NO is produced from L-
arginine by enzyme of nitric oxide synthase (NOS) and the inducible 
isoform of NO (iNOS) during inflammation and iNOS is activated by 
pro-inflammatory cytokines like tumor necrosis factor-α (TNF-
α), interferon-gamma (IFN-γ) and LPS. In lined with the previous 
studies, suppressing these inducers and NO production is crucial to 
inhibit the excessive inflammatory response as present in IBD (Cross 
and Wilson, 2003). For the immunomodulation experiment, the HT-
29 cellular model stimulated with TNF-α is widely used to approve 





(Kechaou et al., 2013). It has been well known that TNF is produced 
by lamina propria mononuclear cells and the levels of that markedly 
increased in IBD patients according to Atreya et al. (2011). Nielsen 
et al. (1997) reported that IL-8, well known as neutrophil 
chemotactic factor and basically secreted cytokines during 
inflammation response, has been also increased in the inflamed 
intestine of patients with IBD. In this study, both the levels of NO in 
LPS-activated RAW264.7 cells and IL-8 in TNF-α stimulated HT-
29 cells were significantly suppressed by Weissella cibaria HS-2 and 
Pediococcus acidilactici NG-4 strains. This result is implicated that 
both strains have the anti-inflammatory property and modulating 
effects of excessive immune response with in vitro study. Besides, 
both selected strains demonstrated an ability to upregulating mRNA 
expression of TJ proteins against TNF-α induced injury. It is well 
proved that treatment of TNF-α to intestinal epithelial cells 
encourages reconstruction of several TJ proteins such as claudin-1, 
occluding and ZO-1 and disrupts epithelial barrier integrity (Cui et 
al., 2010). There are some reports regarding to therapeutic effects of 
probiotics on impaired epithelial barrier function in vitro and in vivo 
study(Gong et al. 2016, Hsieh et al. 2015).  
Because the cause and definite diagnosis of IBD is not clear, there 
has been necessity of a reliable means to quantitate inflammatory 





and Schreiber, 2007). As previously characterized (Strober et al., 
2002), DSS-induced murine colitis models have many common traits 
to human IBD which includes cytokine dysfunction and alteration of 
intestinal microbiota. Therefore, experimental colitic mice induced by 
DSS have been studied effectively as an IBD model and the influence 
of LAB on intestinal inflammation. 
To verify the attenuation effects of selected two kinds of LAB on 
DSS-induced colitis, we treated three kinds of LAB including LGG, 
HS-2 and NG-4 strain daily for 14 days after administration 2.5 % 
and 5 % DSS for three days to C57BL/6 mice. Through the results of 
increased average feed intake, better survival, less DAI scores and 
shortening of the colon length compared to LGG group, these findings 
shows that administration of NG-4 strain significantly attenuates 
inflammation in mice colitis models induced by DSS compared to LGG 
strain.  
With regard to a study of Alex et al. (2008), acute DSS colitis was 
marked by higher production of pro-inflammatory cytokine such as 
IL-6 and TNF-α and regulatory cytokines IL-17 generated by Th-
17. Although our cytokine analysis profile were not accordance with 
these results because there is no control group which was treated 
only DSS, the levels of IL-17 was significantly decreased whereas 
IL-10 production was significantly increased in NG-4 groups at day 





This implicates that NG-4 strain have a tendency to regulate 
inflammatory responses similar to other LABs with previous studies 
(Park et al. 2017, Park et al. 2017).  
According to Herias et al. (2005), a significant increase in the 
levels of Enterobacteriaceae was observed when treatment of DSS. 
Our results which have a tendency to reduce more the levels of that 
in NG-4 group compared to LGG group after 14 days indicate that 
NG-4 strain could regulate and recover the gut microbiota more 
effectively than LGG strain. Based on the report by Vlasova et al. 
(2016), Lactobacillus and Bifidobacteria spp. are recognized as one of 
the main human intestinal microbiota exerting various health-
promoting effects by colonization in the gastrointestinal tracts. The 
treatment of NG-4 strain also showed higher levels of Lactobacillus 
and Bifidobacteria spp. on the day of 14 compared to day of 0, which 
indicates that this strain has probiotic traits to regulate gut microbiota 
positively.  
In line with in vitro results in this study, both HS-2 and NG-4 
groups showed strengthened TJ proteins including claudin-1 and 
occludin compared to LGG groups. According to Zeissig et al. (2007), 
TJ proteins expression in intestine is altered and levels of claudin-1 
expression is decreased significantly. Moreover, the expression of 
ZO-1 have been reported to decline in DSS-induced colitis mice as 





results, both selected LAB are anticipated to have restoration effects 
for impaired TJ proteins. 
In conclusion, our results of in vitro study indicated that selected 
HS-2 and NG-4 strains have been expected to modulate the gut 
microbiota by colonizing well in the host intestine, inhibit colonization 
of pathogens as well as exert anti-inflammatory effects against 
intestinal inflammation by regulating NO and IL-8 productions and 
restoring impaired TJ proteins by TNF-α targeting for IBD patients. 
This previously characterization of selected LAB were verified by 
application to DSS-induced colitis mice models. The groups of NG-4 
treatment showed increased average feed intake, better survival, less 
DAI scores, shortening of the colon length, modulating gut microbiota 
positively and regulating expression of TJ proteins compared to LGG 
group. These results also provide the further proof of Pediococcus 
acidilactici NG-4 as the putative probiotics effective for alleviating 
intestinal inflammation by affecting various mechanisms causing IBD. 
Despite of these encouraging results, additional studies using in vivo 
experiments are requested to deeply elucidate their probiotic 
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Abstract in Korean 
 
궤양성 대장염과 크론병을 포함하는 염증성 장질환 (IBD)은 장관내 
만성 염증에 의해 일어난다. 비록 아직까지 염증성 장질환의 명확한 
발병기전은 밝혀져 있지 않으나, 장내 세균총의 비정상, 장 표피세포의 
장벽 손상, 사이토카인 불균형 그리고 특정 병원균의 감염이 염증성 
장질환을 일으키는 주요한 요인으로 간주되고 있다. 이러한 원인과 
관련하여, 장내 세균총을 유익하게 조절할 수 있는 프로바이오틱스를 
개발하기 위하여 본 실험에서는 염증성 장질환과 관련이 있는 장내 만성 
염증을 완화하는 다양한 기능을 가진 프로바이오틱스 후보군을 선발하고 
특징을 평가하는 것을 목적으로 한다. 먼저, 선택 및 분별 배지를 
이용하여 77개의 전통 발효 식품에서 399개의 유산균을 분리하였다. 
두번째, 기능성이 있는 것으로 기대되는 10개의 균주를 장내 생존성, 
안정성, 장세포 부착성과 같은 기본적인 프로바이오틱 특성에 근거하여 
선별 및 선발하였다. 다음으로, 선발된 유산균 균주가 염증성 장질환과 
관련이 있는 특정 병원균에 대해 항균 활성이 있는지를 평가하기 위해 
disk diffusion, agar well diffusion과 ATP 분석 방법을 통해 확인하였다. 
B4 균주를 제외하고 선발된 거의 모든 균주가 병원균 및 식중독균에 
대해 기준 균주인 LGG와 비교했을 때 저해능을 보였다. 과도한 염증 
반응을 억제하는 선발된 균주의 항염증 효과는 산화질소 분석 방법을  
쥐 대식세포 유래의 RAW264.7 세포주에 적용함으로써 평가되었다. 





처리함으로써 HT-29 세포에서 생성되는 IL-8 농도와 tight junction 
단백질의 발현 수준이 유의적으로 긍정적인 효과를 가지게 조절되었다. 
장내 염증을 완화하는 효과를 가지는지 확인하기 위해 2.5 % 와 5 % 
농도의 DSS를 3일동안 처리함으로써 쥐에 장염을 유발한 이후, LGG, 
HS-2, NG-4 세가지 균주를 14일동안 쥐에 경구투여하였다. NG-4 
균주를 투여한 그룹이 LGG 그룹에 비해 유의적으로 높은 평균 사료 
섭취량과 생존률 및 낮은 DAI 점수를 보였고 장의 길이가 덜 
짧아졌으며, 장내 세균총과 TJ 단백질의 발현을 유익하게 조절하는 
효과를 보였다. 결론적으로, Pediococcus acidilactici NG-4 균주가 임상 
실험 이후, 장내 염증 증상을 완화하기 위해 프로바이오틱스로써 염증성 
장질환 환자에게 적용될 가능성이 있을 것으로 기대된다. 
 
 
 
